TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: In this retrospective survey, we therefore evaluated BV as monotherapy or combination therapy in patients with CD30‐positive PTCL (n  =  9) with regard to treatment regimen, tolerability and efficacy.